Invited Speakers

SRGC
2021

Keynote

Michael T. Longaker, MD, MBA, DSc (hon) FACS


Topic "Wound Repair, Fibroblast Heterogeneity and Fibrosis"

Michael T. Longaker, MD, MBA, DSc (hon) FACS Deane P. and Louise Mitchell Professor and Vice Chair

Co Director, Stanford Institute for Stem Cell Biology and Regenerative Medicine

Director, Children’s Surgical Research

Director, Program in Regenerative Medicine

Professor, by Courtesy, of Bioengineering

Professor, by Courtesy, Department of Materials Science and Engineering

Director, Human Health Initiative

Stanford University School of Medicine

Lucile Salter Packard Children’s Hospital

Michael T. Longaker earned his undergraduate degree at Michigan State University, (where he played varsity basketball and was a member of the 1979 NCAA Men’s Basketball Championship Team) and his medical degree at Harvard Medical School. He completed his surgical residency at the University of California, San Francisco, a residency in Plastic Surgery at NYU and a craniofacial fellowship at UCLA. The majority of his research training took place while he was a Post Doctoral Research Fellow in the Fetal Treatment Program under Dr. Michael Harrison and in the laboratory of Dr. Michael Banda in Radiobiology, both at UCSF. In December 2003, Dr. Longaker earned his M.B.A. from University of California – Berkeley and Columbia University, in the inaugural class of their combined program. He was elected into Beta Gamma Sigma at Columbia Business School, which is the analogous to Phi Beta Kappa for business programs

Dr. Longaker joined the Stanford University School of Medicine on September 1, 2000, as Director of Children’s Surgical Research in the Department of Surgery, Division of Plastic and Reconstructive Surgery and the Lucile Salter Packard Children’s Hospital. In 2003, he was named the Deane P. and Louise Mitchell Professor. As Director of Children’s Surgical Research, Dr. Longaker has the responsibility to develop a children’s surgical research program in the broad areas of developmental biology, epithelial biology and tissue repair, and tissue engineering. Dr. Longaker is the Co- Director of the Stanford Institute of Stem Cell Biology & Regenerative Medicine, as well as the Director of the Program in Regenerative Medicine, Director of Research in the Division of Plastic and Reconstructive Surgery, and has been name Professor, by Courtesy, in the Department of Bioengineering, and Professor, by Courtesy, Department of Materials Science and Engineering. Dr. Longaker is Vice Chair of the Department of Surgery.

Michael Longaker’s extensive research experience includes the cellular and molecular biology of extracellular matrix with specific applications to the differences between fetal and post-natal wound healing, the biology of keloids and hypertrophic scars and the cellular and molecular events that surround distraction osteogenesis with respect to craniofacial development. Most recently he has identified a scar culprit on the dorsum of mice and has blocked mechanotransduction to yield wound regeneration without scarring.

Dr. Longaker is a member of all the major academic surgery societies and was president of both the Society of University Surgeons (2007-08) and the Plastic Surgery Research Council (2006-07). He is one of a handful of surgeons elected into the American Society for Clinical Investigation, Association of Physicians, and National Academy of Medicine. To date, he has over 1300 publications and multiple federal grants to support his research.

Topic "Wound Repair, Fibroblast Heterogeneity and Fibrosis"

Wound healing represents an acute form of fibrosis, in contrast to chronic forms of fibrosis seen in radiation skin injury, adhesions, pulmonary fibrosis, foreign body response, and the desmoplastic /scar reaction that occurs around tumors. There are 100 approximately 100 million new scars per year in the United States between surgery and injuries and this number is 4 to 5 times higher but when taking it worldwide. This talk will review how inhibiting mechanotransduction reduces fibrosis during wound repair. I will review YAP inhibition during wound healing resulting in regeneration rather than scarring. A novel artificial intelligence extra cellular matrix ultrastructure method will be discussed. Lastly, I will be presenting unpublished data using an integrated spatial multi-omics strategy to reveal fibroblast fate during wound repair.




Sarvesh Logsetty, MD, FRCPS, FRCS


Topic: ’Strength through Collaboration. Answering bedside questions with benchside science!’ Sarvesh Logsetty, MD, FRCPS, FRCS Director Manitoba Firefighters Burn Unit Professor Departments of Surgery, Psychiatry, Children’s Health Rady Faculty of Health Sciences University of Manitoba After graduating from the University of Alberta with a Bachelor of Science and M.D in 1990, Dr. Logsetty obtained his Diploma in Clinical Epidemiology from the University of Toronto in 1996. Dr. Logsetty completed the Surgical-Scientist Program at University of Toronto in 1994-1996. He continued his training in fellowships in Acute Burn Care & Reconstructive Surgery at Ross Tilley Burn Centre in Wellesley Hospital in Toronto, Ontario (1996-1998) and in Critical Care of Burns at Harborview Medical Centre in Seattle, Washington (1998-1999). Dr. Logsetty holds certifications with The Royal College of Physicians and Surgeons and the American Board of Surgery.
Dr. Logsetty was Associate Director of the Firefighters Burn Treatment Unit at the University of Alberta Hospital from 1999-2007. In 2007 he was recruited by the University of Manitoba and the Health Sciences Centre to be Provincial Director of the Burn program located at Health Sciences Centre in Winnipeg. He is a Professor of Surgery at the University of Manitoba with cross-appointments to Psychiatry and Pediatrics.
He has dedicated his career to building a strong clinical program and creating a multi-disciplinary program of research specializing in burn and traumatic injury in order to improve patient care. Over his thirty-year career, his goal has been to improve healthcare and healthcare access.
Dr. Logsetty has taught multidisciplinary healthcare students at all levels of education from undergraduates, to established practitioners. Additionally, he has participated in the creation of new and innovative means of delivering educational content. As a result of his success he has been nominated for teaching awards, winning the Top Clinician Award and Patient Advocacy awards. A significant outcome of his teaching is the creation of evidence based standardized care for burn patients for Manitoba. This standardization facilitates referrals, inter-region transfer, and improved overall patient care.
He has rewritten the Burn chapter for the current edition of ATLS, aligning it with ABLS and participated in the conversion to the ATLS mobile learning platform. In January 2016, he recorded the ‘Voice of Experience’ for the Burn chapter of the ATLS mobile edition. Striving to improve burn care throughout the world, he is the lead author of the Essential Burn Management course for Low- and Middle-Income countries. This course has been developed through a grant from CIDA and published under the Canadian Network for International Surgery.
Research based on patient needs is the foundation for his success. All his research questions start with: ‘What is important for the patient?’. He has developed multidisciplinary collaborations with experts in various fields to address these needs. Experts include biomaterials engineers, medical microbiology and infectious disease specialists, administrative data and epidemiology researchers, stem cell and regenerative medicine researchers and community members. By breaking down silos of knowledge, he has developed a robust cross platform program of research that addresses bedside needs with advanced bench side techniques leading to innovations in research approaches, novel strategies and products, and a successful and fruitful learning environment for students. He is widely published in many topics, with over 80 publications and book chapters. Scopus identifies over 1000 citations of his work with an H-index of 18. He holds over $2 million dollars of peer reviewed funding at the Tri-council level as PI, and is a co-investigator on numerous other grants.
Dr. Logsetty has also led the Canadian burn community to a successful CIHR Network catalyst grant application. This funded network has created an annual Canadian Burn symposium, a website for patients and providers alike, a national burn registry organization, is developing a disaster plan for Burn care for Canada, and triggered the formation of a multidisciplinary Canadian Burn Association. The network has coalesced burn care from isolated silos of excellence to a national group that is poised to standardize burn care in the nation and embark on multicenter trials to improve care for Canadians.
More recently Dr. Logsetty has built on his clinical observations that injury disproportionately affects some socioeconomic groups, to investigate social determinants of health. His work on pediatric burn injury and social determinants won the top pediatric burn award at the American Burn Association meeting in 2020. This information will be used to create prevention plans to reduce burn injury in children.




Robert Gniadecki, MD, PhD, DMSci


Topic: Systemic origin of the primary cutaneous lymphomas Robert Gniadecki, MD, PhD, DMSci Director & Professor Faculty of Medicine & Dentistry - Medicine Dept Dermatology University of Alberta

Dr. Robert Gniadecki received his MD degree from Warsaw Medical School (Poland) in 1991 and three years later he obtained his PhD from the Faculty of Health Sciences at Copenhagen University (Denmark) and became a specialist in dermatology in 2001 (certified in Denmark and Canada). In 2010 he was appointed as a full clinical professor at the University of Copenhagen and in 2015 at the University of Alberta, Canada. Dr. Gniadecki has served as a president of the Danish Dermatological Society, treasurer of the Canadian Dermatology Foundation and board members of the ESDR (European Society of Dermatological Research) and ISCL (International Society of Cutaneous Lymphomas). Among major clinical and scientific accomplishments are: development of the low-dose protocol of total skin irradiation for patients with cutaneous lymphomas, the discovery of lymphoma stem cells and introduction of photophoresis and Mohs surgery to dermatology in Denmark. His current scientific activities focus on genomics the experimental therapeutics of cutaneous lymphoma and autoimmune skin diseases and the clinical aspects of the biological treatment of psoriasis.